Vicadrostat
Small molecule
Also known as BI 690517
Evidence outlook · lead readout
NCT06531824 · Kidney Disease, Chronic
The lead readout missed its primary endpoint. The grade and rationale below record what the trial was designed to show and what it found. A further registrational readout is expected around 2026-12-31.
NCT06531824: This was a randomized, quadruple-masked Phase 3 trial with 8371 participants. Its primary endpoint was not met according to the sponsor's announcement of 2026-09-01. A well-designed trial whose primary comparison was not met, or only partly met, is graded moderate.
Also in development:Hypertension · Phase 3Type 2 Diabetes · Phase 3Heart Failure · Phase 3
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT06531824 NCT06531824 · Kidney Disease, Chronic This was a randomized, quadruple-masked Phase 3 trial with 8371 participants. Its primary endpoint was not met according to the sponsor's announcement of 2026-09-01. A well-designed trial whose primary comparison was not met, or only partly met, is graded moderate. Registry: NCT06531824 | 3 | Time to first occurrence of the primary composite outcome of: (i) Kidney disease progression*; or (ii) Hospitalization for heart failure; or (iii) Cardiovascular death. (up to 4 years) 2026-12-31 | Discontinued by Boehringer Ingelheim on an independent Data Monitoring Committee recommendation: accumulating data did not support a meaningful expectation of benefit on the primary composite endpoint vs empagliflozin alone (September 2026). | Partial signal | link ↗ |
View 1 more trial
NCT05182840 NCT05182840 · Kidney Disease, Chronic This was a randomized, quadruple-blind, placebo-controlled phase 2 trial in 586 patients with chronic kidney disease, comparing three doses of vicadrostat (3, 10, and 20 mg) against placebo, all on a background of empagliflozin or placebo. The primary endpoint was the change in urine albumin-to-creatinine ratio (UACR), a physiological measure that defines and stages CKD, at 14 weeks; the 10 mg and 20 mg doses achieved significantly larger reductions than placebo (p<0.0001) and the dose-response analysis was significant, so the primary endpoint was met. The 3 mg dose was only borderline (p=0.0499), making the overall result favorable but clearly dose-dependent. Registry: NCT05182840 | 2 | Change From Treatment Period Baseline in Log Transformed Urine Albumin Creatinine Ratio (UACR) Measured in First Morning Void (FMV) Urine After 14 Weeks - All Patients (The MMRM model is a longitudinal analysis and it incorporated UACR measurements from baseline (Week 6,7 or 8 of the Run-in period) and Week 6, Week 10 and Week 12-14 of Treatment period.); Percent Change of FMV UACR From Baseline to Week 14 Based on Adjusted Median (95% CI) Back Transformed From MMRM Estimate - All Patients (The MMRM model is a longitudinal analysis and it incorporated UACR measurements from baseline (Week 6,7 or 8 of the Run-in period) and Week 6, Week 10 and Week 12-14 of Treatment period.); Change From Baseline to Week 14 in the Log Transformed FMV UACR - Patients With Background Therapy of Placebo Matching Empagliflozin (The MMRM model is a longitudinal analysis and it incorporated UACR measurements from baseline (Week 6,7 or 8 of the Run-in period) and Week 6, Week 10 and Week 12-14 of Treatment period.); Percent Change of FMV UACR From Baseline to Week 14 Based on Adjusted Median (95% CI) Back Transformed From MMRM Estimate - Patients With Background Therapy of Placebo Matching Empagliflozin (The MMRM model is a longitudinal analysis and it incorporated UACR measurements from baseline (Week 6,7 or 8 of the Run-in period) and Week 6, Week 10 and Week 12-14 of Treatment period.); Change From Baseline to Week 14 in the Log Transformed FMV UACR - Patients With Background Therapy of Empagliflozin (The MMRM model is a longitudinal analysis and it incorporated UACR measurements from baseline (Week 6,7 or 8 of the Run-in period) and Week 6, Week 10 and Week 12-14 of Treatment period.); Percent Change of FMV UACR From Baseline to Week 14 Based on Adjusted Median (95% CI) of MMRM Estimate - Patients With Background Therapy of Empagliflozin (The MMRM model is a longitudinal analysis and it incorporated UACR measurements from baseline (Week 6,7 or 8 of the Run-in period) and Week 6, Week 10 and Week 12-14 of Treatment period.) 2023-06-19 | Change in log UACR at week 14 (all patients): 10 mg -0.553 vs placebo -0.066 (difference -0.486, 95% CI -0.660 to -0.313, p<0.0001); 20 mg -0.487 (difference -0.421, 95% CI -0.596 to -0.246, p<0.0001); 3 mg -0.235 (difference -0.168, 95% CI -0.337 to -0.000, p=0.0499). Adjusted median percent change: 10 mg -42.5% vs placebo -6.4%. | Reliable signal | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 3 (4)
What this study did
What this study did
What this study did
What this study did
Phase 2 (3)
What this study did
What this study did
What this study did
Phase 1 (12)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Competitive landscape
Other Aldosterone synthase (CYP11B2) drugs
Baxdrostat, Lorundrostat, QLS1410, SAL0140, VB19055 and 1 more. Compare all 7 Aldosterone synthase (CYP11B2) drugs
6 other tracked programmes target this mechanism, 1 of them ahead of this one.
This drug's own stage for Hypertension: Phase 3. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Vicadrostat: this drug | Phase 3 | Small molecule | Aldosterone synthase (CYP11B2) | not yet graded | No reviewed efficacy summary in this indication | |
| Aprocitentan (Tryvio) | Approved | Small molecule | Endothelin receptor (ETA/ETB, dual) | Reliable signal | NCT03541174: Week 4 sitting systolic blood pressure change: -15.26 vs -11.47 mmHg placebo for aprocitentan 12.5 mg; difference -3.79 mmHg (p=0.0042). For aprocitentan 25 mg: -15.20 vs -11.47 mmHg placebo; difference -3.73 mmHg (p=0.0046). | |
| Baxdrostat (Baxfendy) | Approved | Small molecule | Aldosterone synthase (CYP11B2) | Reliable signal | NCT06168409: Change in 24-hour ambulatory average SBP at week 12: -16.6 mmHg with baxdrostat vs -2.6 mmHg with placebo; between-group difference -14.0 mmHg (95% CI -17.2 to -10.8; p<0.0001). NCT06034743: Change From Baseline in Seated Systolic Blood Pressure for 2 mg Baxdrostat (At Week 12): Double-Blind Treatment Period Weeks 0-12 Baxdrostat 2mg -15.7 mmHg (Standard Error 1) vs Double-Blind Treatment Period Weeks 0-12 Placebo -5.8 mmHg (Standard Error 1) | |
| Propranolol (Inderal LA) | Approved | Small molecule | Beta-1/beta-2 adrenergic receptors | not yet graded | No reviewed efficacy summary in this indication | |
| AD-209 | Phase 3 | Small molecule | Angiotensin II type 1 receptor / L-type calcium channel / Na-Cl cotransporter | Partial signal | NCT06348576: Week-8 sitting systolic blood pressure: non-inferiority and superiority vs telmisartan 40 mg confirmed in the full analysis set (published Phase III, 2026-02-20). | |
| AGSAVI | Phase 3 | Small molecule | Angiotensin II receptor / Calcium channel / Thiazide-like diuretic | Partial signal | No reviewed efficacy summary in this indication | |
| Amlodipine / Valsartan / Rosuvastatin (CJ-30060) | Phase 3 | Small molecule | Angiotensin II receptor / Calcium channel / HMG-CoA reductase | Partial signal | No reviewed efficacy summary in this indication | |
| DWC202206 + DWC202207 | Phase 3 | Small molecule | — | Partial signal | No reviewed efficacy summary in this indication | |
| Esaxerenone (Minnebro) | Phase 3 | Small molecule | Mineralocorticoid receptor | Partial signal | NCT02722265: Change from baseline in sitting SBP/DBP, overall population (n=368): -16.1/-7.7 mmHg at week 12, -18.9/-9.9 mmHg at week 28, -23.1/-12.5 mmHg at week 52 (all 95% CI given); monotherapy subgroup (n=245): -16.3/-7.0 mmHg at week 12, -23.7/-12.3 mmHg at week 52 NCT02807987: Change from baseline in sitting SBP/DBP at end of treatment (Week 12), add-on-to-ARB/ACEI group (n=58): -17.8 mmHg SBP (95% CI -21.0 to -14.7), -8.1 mmHg DBP (95% CI -9.7 to -6.5), p<0.001 | |
| Fimasartan / Atorvastatin / Ezetimibe (BR1017) | Phase 3 | Small molecule | AT1 receptor; NPC1L1; HMG-CoA reductase | Partial signal | NCT05930028: Week 8 co-primary endpoints (full analysis set, 148 randomized): mean sitting systolic BP, fimasartan + atorvastatin/ezetimibe vs atorvastatin/ezetimibe, LS mean difference -7.26 mm Hg (95% CI -12.91 to -1.61), P = 0.0124; LDL-C percent change, fimasartan + atorvastatin/ezetimibe vs fimasartan, LS mean difference -58.02% (95% CI -66.03 to -50.02), P < 0.0001 (Hong et al., Clin Ther 2025). | |
| Levamlodipine / Valsartan (SYH9056) | Phase 3 | Small molecule | Angiotensin II type 1 receptor / L-type calcium channel (dual) | Partial signal | NCT06771245: Blood-pressure lowering significantly superior to levamlodipine or valsartan monotherapy (sponsor, 2026-06-16). | |
| Lorundrostat | Phase 3 | Small molecule | Aldosterone synthase (CYP11B2) | Reliable signal | NCT06153693: Launch-HTN: change from baseline in automated office SBP at Week 6, lorundrostat 50 mg vs placebo: -16.9 mmHg absolute reduction; -9.1 mmHg placebo-adjusted reduction (p<0.0001) NCT05769608: Placebo-adjusted change in 24-hour average ambulatory SBP at Week 12: -7.9 mmHg (lorundrostat 50 mg arm) | |
| Olmesartan / Rosuvastatin (DWJ1276) (Olostar) | Phase 3 | Small molecule | Angiotensin II receptor / HMG-CoA reductase | Partial signal | NCT01764295: LDL-C percent change from baseline at week 8 (LS mean, SE): DWJ1276 (FDC) -52.3% (2.8%) vs olmesartan alone -0.6% (3.5%) vs rosuvastatin alone -46.9% (3.5%) vs placebo -3.2% (3.9%); FDC vs olmesartan difference -51.7% (95% CI -59.8% to -43.6%, P<0.0001). | |
| Orforglipron (Foundayo) | Phase 3 | Small molecule | GLP-1 receptor | not yet graded | No reviewed efficacy summary in this indication | |
| QR12000 | Phase 3 | Small molecule | AT1R; neprilysin | Partial signal | No reviewed efficacy summary in this indication | |
| Sacubitril / Valsartan (Entresto) | Phase 3 | Small molecule | Neprilysin + Angiotensin II receptor (dual) | Partial signal | NCT01599104: Mean sitting systolic BP reduction from baseline at week 8 vs olmesartan (LCZ696/Entresto, Japanese essential hypertension): sacubitril/valsartan 200mg difference -5.01 mmHg (95% CI -6.95 to -3.06, P<0.001 for noninferiority and superiority); 400mg difference -6.97 mmHg (95% CI -8.92 to -5.03, P<0.001). NCT01593787: 43.8% (14/32) of patients reported at least one adverse event (mild severity; 0% serious AEs, 0% deaths); mean sitting SBP reduction 20.5±11.3 mmHg and mean sitting DBP reduction 8.3±6.3 mmHg from baseline to Week 8 (Total LCZ696 group, N=32); geometric mean UACR reduction 15.1%. | |
| Safiglipron (HRS-7535) | Phase 3 | Small molecule | GLP-1 receptor | not yet graded | No reviewed efficacy summary in this indication | |
| SAL0120 | Phase 3 | Small molecule | Endothelin receptor type A (ETA) | not yet graded | No reviewed efficacy summary in this indication | |
| Valsartan / Amlodipine / Chlorthalidone (AJU-C52) | Phase 3 | Small molecule | Angiotensin II receptor / Calcium channel / Thiazide-like diuretic | Reliable signal | NCT06416865: Change in MSSBP from baseline to week 8: between-group difference of -10.99 (valsartan/amlodipine/chlorthalidone vs valsartan/amlodipine control) | |
| Zilebesiran | Phase 3 | RNA / oligonucleotide | Angiotensinogen (AGT) | Reliable signal | NCT04936035: Change From Baseline at Month 3 in 24-hour Mean SBP Assessed by ABPM (Baseline and Month 3): Placebo 6.8 millimeters of mercury (mmHg) ± 1.58 vs Zilebesiran 150 mg Q6M -7.3 millimeters of mercury (mmHg) ± 1.49 vs Zilebesiran 300 mg Q6M and Q3M -10.0 millimeters of mercury (mmHg) ± 1.05 vs Zilebesiran 600 mg Q6M -8.9 millimeters of mercury (mmHg) ± 1.52; p=<0.0001 (Placebo vs Zilebesiran 300 mg Q6M and Q3M), p=<0.0001 (Placebo vs Zilebesiran 600 mg Q6M) | |
| HRS-9563 | Phase 2 | RNA / oligonucleotide | AGT (angiotensinogen) mRNA | not yet graded | No reviewed efficacy summary in this indication | |
| IBI3016 | Phase 2 | RNA / oligonucleotide | Angiotensinogen (AGT) | not yet graded | No reviewed efficacy summary in this indication | |
| QCZ484 | Phase 2 | RNA / oligonucleotide | Angiotensinogen (AGT) | not yet graded | No reviewed efficacy summary in this indication | |
| QLS1410 | Phase 2 | Small molecule | Aldosterone synthase (CYP11B2) | not yet graded | No reviewed efficacy summary in this indication | |
| RTN-001 | Phase 2 | Small molecule | PDE5 | not yet graded | No reviewed efficacy summary in this indication | |
| SAL0140 | Phase 2 | Small molecule | Aldosterone synthase (CYP11B2) | not yet graded | No reviewed efficacy summary in this indication | |
| Tonlamarsen | Phase 2 | RNA / oligonucleotide | Angiotensinogen (AGT) | Partial signal | NCT06864104: Co-primary 1, plasma angiotensinogen change to week 20: monthly tonlamarsen -67.2% vs single dose then placebo -23.0% (LS mean difference -44.1%, 97.5% CI -51.9% to -36.4%; P<0.0001), met. Co-primary 2, office systolic BP change to week 20: -6.7 vs -6.7 mm Hg (LS mean difference -0.1 mm Hg; P=0.97), missed. NCT05314439: (-6% v. -79%, PBO v. 90 mg, p=0.001); median AGT reductions (-5% v. -86%, PBO v. 90 mg) | |
| VB19055 | Phase 2 | Small molecule | Aldosterone synthase (CYP11B2) | not yet graded | No reviewed efficacy summary in this indication | |
| VCT220 | Phase 2 | Small molecule | GLP-1 receptor | not yet graded | No reviewed efficacy summary in this indication | |
| BEBT-701 | Phase 1/2 | RNA / oligonucleotide | Angiotensinogen (AGT) / PCSK9 (dual) | not yet graded | No reviewed efficacy summary in this indication | |
| ADX-850 | Phase 1 | RNA / oligonucleotide | Angiotensinogen (AGT) | not yet graded | No reviewed efficacy summary in this indication | |
| Carvedilol (CKD-385) | Phase 1 | Small molecule | Beta-adrenergic receptors (nonselective) and alpha-1 adrenergic receptor (antagonist) | Partial signal | No reviewed efficacy summary in this indication | |
| HJB647 | Phase 1 | Small molecule | — | not yet graded | No reviewed efficacy summary in this indication | |
| HS-10522 | Phase 1 | Small molecule | — | not yet graded | No reviewed efficacy summary in this indication | |
| JX09 | Phase 1 | Small molecule | Aldosterone synthase (CYP11B2) | Partial signal | No reviewed efficacy summary in this indication | |
| KK3910 | Phase 1 | Biologic (subtype unspecified) | — | not yet graded | No reviewed efficacy summary in this indication | |
| KN060 | Phase 1 | Monoclonal antibody | Factor XI/XIa (FXI/FXIa) | not yet graded | No reviewed efficacy summary in this indication | |
| LivaloV | Phase 1(overall) | Small molecule | HMG-CoA reductase / Angiotensin II type 1 receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Long-Acting ANP Analog (LY3971297) | Phase 1 | Peptide | Natriuretic peptide receptor (NPR-A) | not yet graded | No reviewed efficacy summary in this indication | |
| Nurandociguat | Phase 1 | Small molecule | Soluble guanylate cyclase | Weak signal | No reviewed efficacy summary in this indication | |
| SHR-4658 | Phase 1(overall) | Peptide | — | not yet graded | No reviewed efficacy summary in this indication | |
| C2402 | —(overall) | Small molecule | — | not yet graded | No reviewed efficacy summary in this indication | |
| Candesartan / Amlodipine | —(overall) | Small molecule | Angiotensin II type 1 receptor / L-type calcium channel | not yet graded | No reviewed efficacy summary in this indication | |
| DehydraTECH-CBD | —(overall) | Small molecule | — | not yet graded | No reviewed efficacy summary in this indication | |
| Lercanidipine | —(overall) | Small molecule | L-type calcium channels (Cav1.2) | not yet graded | No reviewed efficacy summary in this indication | |
| OLOMAX | —(overall) | Small molecule | Angiotensin II receptor / Calcium channel / HMG-CoA reductase | not yet graded | No reviewed efficacy summary in this indication | |
| Rosuampin | —(overall) | Small molecule | HMG-CoA reductase / Calcium channel | not yet graded | No reviewed efficacy summary in this indication | |
| N0877 | Discontinued | Small molecule | Angiotensin II receptor / Thiazide diuretic | not yet graded | No reviewed efficacy summary in this indication | |
| SER-100 | Discontinued | Peptide | ORL-1 (nociceptin opioid-like receptor) | Weak signal | Featured results are safety only in this race |
Upcoming events
(6 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow Vicadrostat to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2026 (2)
2028 (2)
Regulatory and conference events
(1)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent